{
  "approved_at_utc": null,
  "subreddit": "investing",
  "selftext": " \n\n* Eli Lilly (NYSE:[LLY](https://seekingalpha.com/symbol/LLY?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link)) gains 20% in premarket on [promising results](https://seekingalpha.com/pr/18145426-lillys-donanemab-slows-clinical-decline-of-alzheimers-disease-in-positive-phase-2-trial?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link) from [Phase 2 TRAILBLAZER-ALZ study](https://clinicaltrials.gov/ct2/show/NCT03367403?cond=trailblazer&draw=2&rank=1&source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link), evaluating donanemab, an antibody that targets a  modified form of beta amyloid called N3pG, for Alzheimer's disease  (AD). The study met the primary endpoint of change from baseline to 76  weeks in AD rating scale.\n* Data  showed that donanemab slowed the decline in a composite measure of  cognition and daily function by 32%, compared to placebo.\n* Safety profile was consistent with observations from Phase 1 data.\n* Full  results of the TRAILBLAZER-ALZ study will be presented at a future  medical congress and submitted for publication in a peer-reviewed  clinical journal.\n* Lilly plans to  discuss these results with regulators to assess next steps for  donanemab. In addition, TRAILBLAZER-EXT is an ongoing trial for those  who participated in TRAILBLAZER-ALZ.\n* Safety, tolerability and efficacy of donanemab are also being evaluated in another [Phase 2 study TRAILBLAZER-ALZ 2](https://clinicaltrials.gov/ct2/show/NCT04437511?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link).\n* Progress on Alzheimer's treatments was one reason cited by BofA in picking Lilly as a [top name for 2021](https://seekingalpha.com/news/3649105-bofas-biopharma-picks-2021-set-to-build-new-launches-beatable-expectations?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link).\n\n[https://seekingalpha.com/news/3650196-eli-lilly-up-20-after-donanemab-shows-clinical-benefit-in-mid-stage-alzheimers-study](https://seekingalpha.com/news/3650196-eli-lilly-up-20-after-donanemab-shows-clinical-benefit-in-mid-stage-alzheimers-study)",
  "author_fullname": "t2_11ysolqg",
  "saved": false,
  "mod_reason_title": null,
  "gilded": 0,
  "clicked": false,
  "title": "Eli Lilly up 20% after donanemab shows clinical benefit in mid-stage Alzheimer's study",
  "link_flair_richtext": [],
  "subreddit_name_prefixed": "r/investing",
  "hidden": false,
  "pwls": 6,
  "link_flair_css_class": null,
  "downs": 0,
  "top_awarded_type": null,
  "hide_score": false,
  "name": "t3_kv332t",
  "quarantine": false,
  "link_flair_text_color": "dark",
  "upvote_ratio": 0.91,
  "author_flair_background_color": null,
  "subreddit_type": "public",
  "ups": 42,
  "total_awards_received": 0,
  "media_embed": {},
  "author_flair_template_id": null,
  "is_original_content": false,
  "user_reports": [],
  "secure_media": null,
  "is_reddit_media_domain": false,
  "is_meta": false,
  "category": null,
  "secure_media_embed": {},
  "link_flair_text": null,
  "can_mod_post": false,
  "score": 42,
  "approved_by": null,
  "author_premium": false,
  "thumbnail": "",
  "edited": false,
  "author_flair_css_class": null,
  "author_flair_richtext": [],
  "gildings": {},
  "content_categories": null,
  "is_self": true,
  "mod_note": null,
  "created": 1610402130,
  "link_flair_type": "text",
  "wls": 6,
  "removed_by_category": null,
  "banned_by": null,
  "author_flair_type": "text",
  "domain": "self.investing",
  "allow_live_comments": false,
  "selftext_html": "<!-- SC_OFF --><div class=\"md\"><ul>\n<li>Eli Lilly (NYSE:<a href=\"https://seekingalpha.com/symbol/LLY?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">LLY</a>) gains 20% in premarket on <a href=\"https://seekingalpha.com/pr/18145426-lillys-donanemab-slows-clinical-decline-of-alzheimers-disease-in-positive-phase-2-trial?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">promising results</a> from <a href=\"https://clinicaltrials.gov/ct2/show/NCT03367403?cond=trailblazer&amp;draw=2&amp;rank=1&amp;source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">Phase 2 TRAILBLAZER-ALZ study</a>, evaluating donanemab, an antibody that targets a  modified form of beta amyloid called N3pG, for Alzheimer&#39;s disease  (AD). The study met the primary endpoint of change from baseline to 76  weeks in AD rating scale.</li>\n<li>Data  showed that donanemab slowed the decline in a composite measure of  cognition and daily function by 32%, compared to placebo.</li>\n<li>Safety profile was consistent with observations from Phase 1 data.</li>\n<li>Full  results of the TRAILBLAZER-ALZ study will be presented at a future  medical congress and submitted for publication in a peer-reviewed  clinical journal.</li>\n<li>Lilly plans to  discuss these results with regulators to assess next steps for  donanemab. In addition, TRAILBLAZER-EXT is an ongoing trial for those  who participated in TRAILBLAZER-ALZ.</li>\n<li>Safety, tolerability and efficacy of donanemab are also being evaluated in another <a href=\"https://clinicaltrials.gov/ct2/show/NCT04437511?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">Phase 2 study TRAILBLAZER-ALZ 2</a>.</li>\n<li>Progress on Alzheimer&#39;s treatments was one reason cited by BofA in picking Lilly as a <a href=\"https://seekingalpha.com/news/3649105-bofas-biopharma-picks-2021-set-to-build-new-launches-beatable-expectations?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">top name for 2021</a>.</li>\n</ul>\n\n<p><a href=\"https://seekingalpha.com/news/3650196-eli-lilly-up-20-after-donanemab-shows-clinical-benefit-in-mid-stage-alzheimers-study\">https://seekingalpha.com/news/3650196-eli-lilly-up-20-after-donanemab-shows-clinical-benefit-in-mid-stage-alzheimers-study</a></p>\n</div><!-- SC_ON -->",
  "likes": null,
  "suggested_sort": null,
  "banned_at_utc": null,
  "view_count": null,
  "archived": false,
  "no_follow": false,
  "is_crosspostable": false,
  "pinned": false,
  "over_18": false,
  "awarders": [],
  "media_only": false,
  "can_gild": false,
  "spoiler": false,
  "locked": false,
  "author_flair_text": null,
  "treatment_tags": [],
  "visited": false,
  "removed_by": null,
  "num_reports": null,
  "distinguished": null,
  "subreddit_id": "t5_2qhhq",
  "mod_reason_by": null,
  "removal_reason": null,
  "link_flair_background_color": "",
  "id": "kv332t",
  "is_robot_indexable": true,
  "report_reasons": null,
  "author": "Omg_Keynes",
  "discussion_type": null,
  "num_comments": 7,
  "send_replies": false,
  "whitelist_status": "all_ads",
  "contest_mode": false,
  "mod_reports": [],
  "author_patreon_flair": false,
  "author_flair_text_color": null,
  "permalink": "/r/investing/comments/kv332t/eli_lilly_up_20_after_donanemab_shows_clinical/",
  "parent_whitelist_status": "all_ads",
  "stickied": false,
  "url": "https://www.reddit.com/r/investing/comments/kv332t/eli_lilly_up_20_after_donanemab_shows_clinical/",
  "subreddit_subscribers": 1275613,
  "created_utc": 1610496697,
  "num_crossposts": 0,
  "media": null,
  "is_video": false,
  "original_created_utc": 1610373330,
  "the_new_excerpt": " * Eli Lilly (NYSE:LLY\n   [https://seekingalpha.com/symbol/LLY?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link])\n   gains 20% in premarket on promising results\n   [https://seekingalpha.com/pr/18145426-lillys-donanemab-slows-clinical-decline-of…"
}